1-10 of 10
T Facon
Close
Sort by
Journal Articles

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Paul Richardson, A. Jakubowiak, J. Wolf, J. Allerton, J. Zonder, S. Lonial, A. Krishnan, J. Densmore, I. Ghobrial, K. Colson, T. Kendall, C. Leister, B. Martineau, T. Hideshima, T. Facon, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson
Journal: Blood
Blood (2007) 110 (11): 1170.
https://doi.org/10.1182/blood.V110.11.1170.1170
Published: 2007
Journal Articles

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer, T. Facon, J. Harousseau, A. Boral, K.C. Anderson
Journal: Blood
Blood (2006) 108 (11): 3529.
https://doi.org/10.1182/blood.V108.11.3529.3529
Published: 2006
Journal Articles

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

J.F. San Miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 366.
https://doi.org/10.1182/blood.V106.11.366.366
Published: 2005
Journal Articles

A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.

Ibrahim Yakoub-Agha, C. Hulin, C. Doyen, L. Benboubker, L. Voillat, K. Bouabdallah, G. Guillerm, P. Moreau, F. Maloisel, A.M. Stoppa, B. Pegourie, P. Rodon, M. Dib, P. Casassus, B. Slama, E. Voog, H. Jardel, P. Collet, M. Wettervald, A.M. Peny, P. Mineur, C. Duguet, R. Zerbib, T. Facon, J.Y. Mary
Journal: Blood
Blood (2005) 106 (11): 364.
https://doi.org/10.1182/blood.V106.11.364.364
Published: 2005
Journal Articles

Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

Andreas Hochhaus, M. Baccarani, C. Sawyers, A. Nagler, T. Facon, S.L. Goldberg, F. Cervantes, R.A. Larson, M. Voi, R. Ezzeddine, H. Kantarjian
Journal: Blood
Blood (2005) 106 (11): 41.
https://doi.org/10.1182/blood.V106.11.41.41
Published: 2005
Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 3474.
https://doi.org/10.1182/blood.V106.11.3474.3474
Published: 2005
Journal Articles

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 2547.
https://doi.org/10.1182/blood.V106.11.2547.2547
Published: 2005
Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson
Journal: Blood
Blood (2004) 104 (11): 1479.
https://doi.org/10.1182/blood.V104.11.1479.1479
Published: 2004
Journal Articles

Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis

JL Lai, M Zandecki, JY Mary, F Bernardi, V Izydorczyk, M Flactif, P Morel, JP Jouet, F Bauters, T Facon
Journal: Blood
Blood (1995) 85 (9): 2490–2497.
https://doi.org/10.1182/blood.V85.9.2490.bloodjournal8592490
Published: 1995
Journal Articles

Double-intensive therapy in high-risk multiple myeloma

JL Harousseau, N Milpied, JP Laporte, P Collombat, T Facon, JD Tigaud, P Casassus, F Guilhot, N Ifrah, C Gandhour
Journal: Blood
Blood (1992) 79 (11): 2827–2833.
https://doi.org/10.1182/blood.V79.11.2827.2827
Published: 1992